Compounders Sue FDA; Young Women in Perimenopause; More Osteoporosis Biosimilars

A group representing compounding pharmacies sued the FDA over the removal of semaglutide (Ozempic, Wegovy) from the agency’s drug shortage list. (The Hill)

Investigational pilavapadin — an oral, non-opioid adaptor-associated kinase 1 inhibitor — achieved meaningful reductions in diabetic peripheral neuropathic pain compared with placebo in a phase IIb trial, said Lexicon Pharmaceuticals.

A significant number of women ages 30 to 45 said they experience perimenopause-related symptoms, according to a study with 4,432 U.S. participants. (npj Women’s Health)

The CDC will stop processing transgender identity data as part of its health surveillance. (STAT)

Medicare Part D spending on selected GLP-1 and SGLT-2 inhibitor drugs was up 364% from 2019 to 2023, according to a report from the HHS Office of Inspector General.

High-dose multivitamins and multi-minerals either alone or with edetate disodium-based chelation didn’t help prevent cardiovascular events in a randomized trial of people with diabetes and a history of heart attack. (JAMA Internal Medicine)

The large market of ultraprocessed foods for babies and toddlers has experts worried. (STAT)

Prevalence of diabetic retinal disease increased every year from 2007 through 2021, but incidence rates of its vision-threatening components, diabetic macular edema, and proliferative diabetic retinopathy improved. (Ophthalmology)

The FDA approved two more denosumab biosimilars, Stoboclo and Osenvelt, referencing Prolia and Xgeva, respectively, said maker Celltrion.

Corcept Therapeutics announced that it sent data on relacorilant — a selective cortisol modulator to treat endogenous hypercortisolism — to the FDA seeking approval.

Please enable JavaScript to view the

comments powered by Disqus.